Arbutus Biopharma Logo
Tekmira Closes $5.1 Million Public Offering
June 16, 2011 08:48 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, June 16, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, has closed its...
Arbutus Biopharma Logo
Tekmira Prices Public Offering
June 09, 2011 08:59 ET | Arbutus Biopharma Corporation
VANCOUVER, B.C., June 9, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today it has...
Arbutus Biopharma Logo
Tekmira Announces Proposed Public Offering
June 08, 2011 16:02 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, June 8, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira's LNP Delivery Technology Enables Proof of RNAi in Man and Clinical Activity
June 06, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, B.C., June 6, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided comments on...
Arbutus Biopharma Logo
Tekmira Files Amended Complaint in Alnylam Litigation
June 03, 2011 17:19 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, June 3, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed...
Arbutus Biopharma Logo
Tekmira Expands Oncology Pipeline With RNAi Therapeutic Targeting Novel Cancer Genes WEE1 and CSN5
June 02, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, B.C., June 2, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has...
Arbutus Biopharma Logo
Tekmira Presents LNP Technology Innovations at Scientific Symposium
May 26, 2011 16:47 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 26, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira to Present at the ThinkEquity 2nd Annual Healthcare Conference
May 19, 2011 16:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 19, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira and Bristol-Myers Squibb Expand Collaboration to Include Broader Applications of LNP Technology
May 17, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 17, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Provides Corporate Update and Announces First Quarter 2011 Results
May 10, 2011 16:00 ET | Arbutus Biopharma Corporation
VANCOUVER, B.C., May 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its financial and...